Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $58.8 million.

  • Regenxbio's Cash & Equivalents rose 385.93% to $58.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.8 million, marking a year-over-year increase of 385.93%. This contributed to the annual value of $57.5 million for FY2024, which is 6663.58% up from last year.
  • Per Regenxbio's latest filing, its Cash & Equivalents stood at $58.8 million for Q3 2025, which was up 385.93% from $79.6 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Cash & Equivalents registered a high of $345.2 million during Q4 2021, and its lowest value of $34.5 million during Q4 2023.
  • For the 5-year period, Regenxbio's Cash & Equivalents averaged around $127.9 million, with its median value being $97.0 million (2022).
  • In the last 5 years, Regenxbio's Cash & Equivalents surged by 31993.63% in 2021 and then crashed by 7191.5% in 2022.
  • Over the past 5 years, Regenxbio's Cash & Equivalents (Quarter) stood at $345.2 million in 2021, then tumbled by 71.91% to $97.0 million in 2022, then crashed by 64.39% to $34.5 million in 2023, then skyrocketed by 66.64% to $57.5 million in 2024, then grew by 2.22% to $58.8 million in 2025.
  • Its Cash & Equivalents was $58.8 million in Q3 2025, compared to $79.6 million in Q2 2025 and $130.1 million in Q1 2025.